Exosome Therapy vs Finasteride for Hair Loss: Which is best for you?
Finasteride is one of only two treatments with a UK licence for pattern hair loss. It has been studied in clinical trials for decades, it is prescribed by dermatologists as a first-line option for men, and it has a strong evidence base. It also has a side effect profile that the MHRA has issued multiple Drug Safety Updates about, and which is worth understanding properly before starting treatment.
We’ll also explain why finasteride and exosome therapy are not necessarily competing: they work on different parts of the same problem, and for some patients they make more sense together than as alternatives.
Book your consultation
Finasteride is a licensed prescription-only medicine for male pattern hair loss.
Finasteride is not licensed for women of childbearing age.
Exosome therapy works on follicle biology directly, not on hormone levels.
The two treatments work on different mechanisms and may be complementary.
Finasteride vs. Exosomes: The Short Answer
Finasteride is a highly effective first-line treatment for male pattern hair loss. For men who are suitable candidates, it addresses the root hormonal cause of androgenetic alopecia in a way that no other licensed medicine does. Its evidence base is one of the strongest in hair loss medicine.
The trade-off is a side effect profile that requires informed consent and careful monitoring. The MHRA has strengthened its safety warnings for finasteride twice in recent years. That does not make it the wrong choice for everyone, but it does make it a choice that should be made with your prescriber, not a pharmacist counter purchase.
Exosome therapy works differently. It does not suppress hormones. It delivers growth signals directly to struggling follicles. It cannot replace finasteride's hormonal action, but it can work alongside it on a different part of the problem. For men already on finasteride who want to address follicle regeneration as well as hormone suppression, exosome therapy is a rational consideration.
| Exosome therapy (Hair Revive protocol) | Finasteride | |
|---|---|---|
| What it is | Unlicensed clinic-based treatment using salmon-derived exosome preparation | Licensed prescription medicine, DHT inhibitor |
| How it works | Delivers growth factors and microRNA directly to follicle cells | Reduces scalp DHT by ~60–70%, slowing follicle miniaturisation |
| UK regulatory status | Unlicensed ATMP category; Hair Revive protocol sits outside the MHRA's specific injection and human-biologicals concerns | Licensed Prescription Only Medicine (POM); private prescription required for AGA |
| Evidence base | Emerging: 2025 systematic review of 11 studies, 2 RCTs | Very strong: decades of RCTs; 80–90% stabilisation or improvement at 2 years in men |
| NICE / NHS | Not NICE-recommended or NHS-provided | Not funded on the NHS for AGA; not NICE-recommended for prescribing in primary care |
| Who can use it | Suitable for men and women (except fish allergy; specific clinical contraindications) | Licensed for adult men only; contraindicated in women of childbearing age |
| Commitment | Mild scalp redness; transient sensitivity; fish allergy contraindication | Sexual dysfunction (may persist after stopping); psychiatric effects including depression and suicidal ideation (MHRA warnings) |
| Where you get it | CQC-registered clinic under GMC-registered medical oversight | Private prescription from a GP or dermatologist; online prescribing services |
The Core Difference: Hormonal Suppression vs Follicle Stimulation
Finasteride and exosome therapy target different points in the same process, which is why they are potentially complementary rather than competing.
Finasteride
Removing the cause
Androgenetic alopecia is driven by DHT acting on genetically susceptible follicles. Finasteride removes most of that hormonal signal, which slows or stops the driver of the disease. In men who respond, the miniaturisation process decelerates, shedding reduces, and in many cases some degree of regrowth occurs as follicles that were suppressed rather than destroyed recover.
The limitation is that finasteride does not directly stimulate or regenerate follicles. It creates a more favourable hormonal environment, but it does not itself deliver the growth signals that follicles need to recover. In men with significant miniaturisation already established before treatment, stabilisation is the more common outcome than substantial regrowth.
Exosomes
Working on the follicle directly
Exosome therapy operates below the hormonal level. The growth factors and microRNA in the E50 preparation target follicle cell activity: activating the growth phase, supporting dermal papilla cell health, promoting the blood supply around follicles, and in some cases counteracting residual androgen-mediated suppression via microRNA pathways. It does not reduce DHT. But in follicles that have already been miniaturised by prior DHT exposure, it may be able to support recovery that finasteride alone cannot achieve.
The combination logic follows from this. A patient on finasteride has addressed the driver of the disease but may still have follicles that are recovering from prior miniaturisation. Exosome therapy can address that follicle-level regeneration alongside finasteride's hormonal action.
The Side Effect Picture of Finasteride
This section covers the MHRA's position on finasteride's side effects in full.
We include it because patients researching finasteride deserve complete information, and because understanding the side effect profile is relevant to the comparison with exosome therapy, which has a significantly different and milder safety record.
Finasteride
Sexual side effects
The current Propecia Summary of Product Characteristics (SmPC), revised by the MHRA in December 2024, lists the following frequencies from clinical trials:
Decreased libido: 1.8% (placebo: 1.3%)
Erectile dysfunction: 1.3% (placebo: 0.7%)
Decreased ejaculate volume: 0.8% (placebo: 0.4%)
A 2018 meta-analysis in the British Journal of Dermatology pooling fifteen RCTs (4,495 participants) found a pooled relative risk of sexual dysfunction for finasteride specifically of 1.66 (95% CI 1.20 to 2.30). That means the risk is statistically real and measurable across controlled trials, not just anecdote.
In the long-term trial data, sexual side effects reported during year one declined significantly by years four and five in many patients, both in those who continued treatment and those who stopped. Resolution in the majority of men during ongoing use is documented in the clinical trial record.
Finasteride
Psychiatric effects
The MHRA issued a Drug Safety Update in May 2017 on rare reports of depression and suicidal ideation with finasteride. It advised prescribers to discuss this risk with patients before starting treatment and to advise immediate discontinuation if mood changes develop.
In April 2024, the MHRA strengthened these warnings further and introduced a mandatory patient alert card to be dispensed with finasteride. The April 2024 SmPC includes mood alterations including depressed mood and depression, and suicidal ideation, as listed risks.
Finasteride
Post-finasteride syndrome
Post-finasteride syndrome (PFS) describes persistent adverse effects, principally sexual dysfunction and neuropsychiatric symptoms, that continue for at least three months after stopping finasteride.
The term is not formally used in MHRA regulatory documents, but the underlying phenomenon is acknowledged: the current Propecia SmPC explicitly states that "persistence of sexual dysfunction... after discontinuation has been reported post-marketing," and the MHRA's Yellow Card data includes reports recorded as not recovered or not resolved.
The scientific status of PFS is actively debated. Researchers who are sceptical point to selection bias in PFS study populations and to the well-documented nocebo effect: a 2007 randomised trial found that men who were explicitly told about sexual side effects before starting treatment were three times more likely to report them than those who were not told.
Critics of that position note that a pharmacological signal clearly exists in the trial data even in uninformed patients, and that the MHRA's acknowledgement of post-discontinuation persistence is not consistent with a pure nocebo explanation.
Finasteride
What this means in practice
These are real side effects in a subset of patients. They are not universal, and for the majority of men who take finasteride the treatment is well tolerated. They are also acknowledged at the highest UK regulatory level, and patients starting finasteride should have this discussion with their prescriber before they begin.
If you are considering finasteride, a GP or dermatologist is the right person to have that conversation with. That is not Hair Revive's role, and we do not prescribe it. If you have stopped finasteride due to side effects and are looking for a non-hormonal alternative to support your hair loss, exosome therapy is a conversation we can have.
Exosomes
And Exosomes?
Comparatively, side effects from Exosome treatment are minimal.
You can expect Mild scalp redness and, transient sensitivity in some cases. This is by far one of the main reasons we see people come to us.
What the Research Shows
This is where the two treatments differ most clearly.
Finasteride
Strong but fraught long-standing evidence
he pivotal clinical evidence for finasteride in male AGA is a programme of RCTs published in the late 1990s, with five-year data published subsequently. In the large, controlled trials:
Hair counts at the vertex (the area most commonly treated) increased by a mean of around 100 to 140 hairs in a one-inch circle versus placebo at years one and two
Hair counts at the vertex (the area most commonly treated) increased by a mean of around 100 to 140 hairs in a one-inch circle versus placebo at years one and two
At five years, patients on finasteride had a 93% lower likelihood of developing further visible hair loss compared to placebo
Approximately 80 to 90% of men achieved stabilisation or improvement at two years; around 48% showed visible regrowth
A 2025 network meta-analysis in Frontiers in Medicine across multiple RCTs identified the finasteride and minoxidil combination as the most effective treatment in male AGA, outperforming either agent alone.
Like minoxidil, finasteride requires continuous use. Stopping treatment returns DHT levels to pre-treatment concentrations within approximately two weeks, and hair loss resumes within six to twelve months.
Exosomes
Exciting emerging evidence
A 2025 systematic review in Clinical, Cosmetic and Investigational Dermatology of eleven clinical studies (including two RCTs) found density increases of 9.5 to 35 hairs per cm² across the study population, with mild and transient adverse events only.
The evidence is considerably earlier stage than for finasteride: the studies are smaller, the follow-up is shorter, and the evidence does not yet carry the weight of decades of randomised controlled trials.
Exosomes
Our Experience at Hair Revive
We began offering E50 Treatment to our clinic in early 2025.
The pattern we see in practice is broadly consistent with what the wider exosome literature reports: where patients have early-to-mid-stage pattern hair loss and follicles are still present, many go on to see improvements in density and hair condition over the course of treatment.
In cases where follicles are no longer active or the hair loss is advanced, the response is limited, which is why we assess every patient before agreeing a course.
This is clinical observation from practice, not a published audit, and we describe it that way. It informs how we approach patient selection and contributes to our confidence in the protocol. It is not a substitute for peer-reviewed evidence, and we are not presenting it as such.
Clinical Observations at The Hair Revive Clinic
We've proudly offered E50-H Treatment for over a year in our Clinic and tracked our own visitors progress over time.
Visit our Results Page to some of the transformations we've achieved:
VISITOR RESULTS →
The UK Regulatory Picture
The regulatory position for each treatment is different, and it is worth understanding why.
Finasteride
Licensed but Ever Changing
Finasteride 1mg is a licensed POM in the UK with full MHRA regulatory oversight. The MHRA has issued multiple Drug Safety Updates and required label changes as post-marketing evidence has developed.
That is pharmacovigilance working as it should: a licensed medicine, actively monitored, with safety information updated as reports accumulate. The April 2024 patient alert card requirement reflects the MHRA's continuing attention to this medicine's safety profile.
Evolving
Evolving
The MHRA classifies exosomes as advanced therapy medicinal products (ATMPs). No exosome product holds a UK marketing authorisation for hair loss. The MHRA has been specifically concerned about injected exosomes in aesthetic procedures, and UK cosmetics regulation separately restricts human-derived biological material in cosmetic contexts.
Note that neither of those specific concerns describes what we do at Hair Revive, where the preparation is salmon-derived, topical rather than injected, and provided under medical oversight.
Can They Be Used Together?
Yes, and there is a strong mechanistic case for it.
Finasteride reduces the hormonal signal driving follicle miniaturisation. Exosome therapy delivers growth signals that work at the follicle cell level: activating the growth phase via Wnt/beta-catenin signalling, promoting blood vessel formation via VEGF, and supporting dermal papilla cell health. These mechanisms are genuinely complementary: one addresses the cause, the other addresses follicle recovery.
A 2025 systematic review of stem cell-derived exosome therapy notes that exosomal microRNA can antagonise residual DHT-mediated follicle suppression via specific signalling pathways, suggesting the combination may be more than simply additive. Preclinical research has also tested hybrid delivery systems combining exosomes with finasteride, showing improvements in follicular delivery and bioavailability compared to either alone.
The clinical caveat is important: no published RCT has yet tested finasteride combined with exosome therapy specifically in a human clinical trial. Some exosome studies excluded patients on finasteride to keep the study populations clean. The combination is biologically plausible and grounded in published mechanistic evidence, but clinical proof of additive benefit in humans is not yet established.
The Bottom Line: Which Treatment is Right for You?
A consultation will take account of your current medications, your history with any previous treatments, and your pattern of loss before advising on next steps.
Finasteride
You are a man with male pattern hair loss in early to moderate stages
You want a licensed, evidence-based daily treatment that addresses the hormonal driver of AGA
You have been counselled on the side effect profile and are comfortable proceeding after that conversation
You are male
Exosomes
You have tried finasteride and discontinued due to side effects
You are a woman with pattern hair loss (for whom finasteride is contraindicated unless post-menopausal under specialist supervision)
You are already on finasteride and want to address follicle regeneration alongside hormonal suppression
You prefer a clinic-based course of treatment without a daily medication commitment
Neither treatment is the right answer if:
Follicles in the target area have reached full dormancy (a transplant conversation is more appropriate)
You have a scarring alopecia
You have a medical condition that makes either treatment clinically unsuitable
Is Exosome Hair Restoration Therapy Right For You?
In a world of endless serums, tinctures and procedures it's easy to feel like you're going round in circles.
Exosome Therapy isn't for everybody, and we're upfront about that.
Our 2 Minute Suitability Quiz helps you get a clear picture on whether to proceed with this Treatment or not.
Frequently Asked Questions About Finasteride
For men with male pattern hair loss who are suitable candidates, finasteride has a considerably stronger evidence base today. It is a licensed, well-studied medicine with decades of randomised controlled trial data. Exosome therapy has a smaller but growing body of evidence and works through a different mechanism. The more useful question for most patients is whether finasteride is appropriate for them specifically (which requires a conversation with a prescriber) rather than a blanket ranking.
Yes. Exosome therapy does not involve any hormonal action and has a different and considerably milder side effect profile. The most commonly reported effects are mild, temporary scalp redness and sensitivity at the treatment site. It is a reasonable consideration for people who have found finasteride unsuitable. A consultation will look at your pattern of loss and advise on the most appropriate approach.
In principle, yes. The two treatments work on different mechanisms and do not conflict. A consultation at Hair Revive will review any existing medications and plan the treatment accordingly.
For the majority of men it is well tolerated, and for most who do experience side effects those effects resolve during treatment or after stopping. The MHRA has issued Drug Safety Updates on sexual dysfunction (which may persist after stopping in a minority of patients) and psychiatric effects including depression and suicidal ideation. The right person to assess whether finasteride is appropriate and safe for you specifically is your prescriber, who can review your full medical history and discuss the balance of risks and benefits for your case.
Post-finasteride syndrome (PFS) is a term used to describe persistent adverse effects, particularly sexual dysfunction and neuropsychiatric symptoms, that continue for at least three months after stopping finasteride. The MHRA does not formally use this term, but does explicitly acknowledge that sexual dysfunction has persisted after discontinuation in some patients, and its Yellow Card data includes post-discontinuation reports recorded as unresolved. The scientific evidence on PFS is contested, but the persistence of some adverse effects after stopping is acknowledged at the regulatory level.
Finasteride is contraindicated in women of childbearing age due to a serious risk of birth defects if taken during pregnancy. It is sometimes used off-label in post-menopausal women under specialist supervision, but this is outside the licensed indication and requires specialist clinical assessment. The NHS describes finasteride as "generally not recommended for women." For women with pattern hair loss, minoxidil and exosome therapy are more commonly appropriate options.
No. Finasteride for hair loss is available only on a private prescription and is not funded by the NHS for this indication.
The Best Time To Start Your Hair Restoration Journey? Yesterday.
The second best time? TODAY!
If you're ready to start making meaningful progress towards fuller, thicker hair, then get in touch today.
We are honest and transparent about your potential, and will always set clear expectations, even before you visit us.
So what have you got to lose? Get in touch Today.
Book Online
Call
Text
Visit
Hair Revive at Dr Aesthetica
Unit 1, 1431–1433 Bristol Road South
Birmingham, West Midlands B31 2SU